In recent years developmental advances in biology at the molecular level have given rise to improving mortality and increasing longevity in the human species. As a consequence there has been a significant and growing risk affecting a number of financial institutions who have traditionally insured human life or provided financial provision for retirement. These institutions can no longer warehouse this risk or successfully fund it. This has raised a serious economic spectre. This talk explores the recent developments, the level of longevity exposure and the solutions put forward in what is seen by the financial markets as the search for the holy-grail.